[CH2:1]([O:3][C:4](=[O:37])[CH2:5][C@@H:6]([N:10]1[C:14]2[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=2[N:12]([CH2:19][C:20]2[CH:25]=[C:24]([Br:26])[CH:23]=[C:22]([N+:27]([O-])=O)[C:21]=2[S:30][C:31](=[O:35])N(C)C)[C:11]1=[O:36])[CH2:7][CH2:8][CH3:9])[CH3:2].C(O)C.[Sn](Cl)(Cl)(Cl)Cl>C(OC(=O)C)C>[CH2:1]([O:3][C:4](=[O:37])[CH2:5][C@@H:6]([N:10]1[C:14]2[CH:15]=[CH:16][CH:17]=[CH:18][C:13]=2[N:12]([CH2:19][C:20]2[C:21]3[S:30][C:31](=[O:35])[NH:27][C:22]=3[CH:23]=[C:24]([Br:26])[CH:25]=2)[C:11]1=[O:36])[CH2:7][CH2:8][CH3:9])[CH3:2](S)-3-[3-(5-Bromo -2-dimethylcarbamoylsulfanyl-3-nitro-benzyl)-2-oxo-2,3-dihydro-benzimidazol-1-yl]-hexanoic acid ethyl ester (70 mg, 0.11 mmol) is suspended in ethylacetate (0.5 mL)/ethanol (0.5 mL) and then tin chloride (133 mg, 0.6 mmol) is added. The resulting suspension is equipped with a reflux condenser and heated to 75° C. for 1 hour. Upon completion the reaction is cooled to room temperature and the solvents evaporated in vacuo. The resulting solid is taken up in ethyl acetate and the product is filtered. The solvent is evaporated in vacuo and the resulting solid is purified via prep reverse phase LC to give 33 mg (54%) of the title compound. LCMS (ESMS): m/z 519.7 (M+H+).
Wird geladen…